Last Thursday, DOJ announced that Astellas Pharma US Inc. and Amgen Inc. have agreed to pay a total of $124.75 million to resolve FCA allegations arising from their illegal Medicare copayments for their own products, orchestrated through purportedly independent foundations that were used as mere pass through entities.